Beyond protein detection, the identification of PCa-specific nucleic acid biomarkers, such as PCA3 and TMPRSS2–ERG gene fusions, has emerged as a key strategy for early diagnosis, risk stratification, and treatment planning. The gene discussed is PCA3; the disease is posterior cortical atrophy.